FDA ganaxolone coverage for business development, investment, and market access teams
Ztalmy has received FDA approval as the first treatment for CDKL5 deficiency seizures, marking a significant advancement in managing this rare genetic disorder.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
